BeOne Medicines (ONC) Total Non-Current Liabilities (2015 - 2026)
BeOne Medicines (ONC) posted quarterly Total Non-Current Liabilities of $2.0 billion for Q1 2026, up 453.09% year-over-year from $358.3 million in Q1 2025, and down 0.84% quarter-over-quarter from $2.0 billion in Q4 2025.
BeOne Medicines (ONC) Total Non-Current Liabilities (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Total Non-Current Liabilities for 12 consecutive years, with $2.0 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 453.09% year-over-year to $2.0 billion; the TTM figure through Mar 2026 stood at $2.0 billion (up 453.09% YoY), while the FY2025 annual figure was $2.0 billion, up 434.67% from the prior year.
- Total Non-Current Liabilities slipped to $2.0 billion in Q1 2026 per ONC's latest filing, from $2.0 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $2.0 billion in Q4 2025 and bottomed at $318.1 million in Q2 2025.
- Historically, Total Non-Current Liabilities has averaged $705.7 million across 5 years, with a median of $525.1 million in 2023.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities sank 34.35% — and 2026, when it surged 453.09%.
- BeOne Medicines' Total Non-Current Liabilities stood at $527.4 million in 2022, then slipped by 13.19% to $457.8 million in 2023, then decreased by 18.36% to $373.8 million in 2024, then surged by 434.67% to $2.0 billion in 2025, then decreased by 0.84% to $2.0 billion in 2026.
- Business Quant data shows ONC's Total Non-Current Liabilities at $2.0 billion in Q1 2026, $2.0 billion in Q4 2025, and $1.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 378.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.88 Bn |
| Mar 31, 2026 | 1.98 Bn |
| Dec 31, 2025 | 2.00 Bn |
| Sep 30, 2025 | 1.13 Bn |
| Jun 30, 2025 | 318.08 Mn |
| Mar 31, 2025 | 358.29 Mn |
| Dec 31, 2024 | 373.79 Mn |
| Sep 30, 2024 | 369.46 Mn |
| Jun 30, 2024 | 407.16 Mn |
| Mar 31, 2024 | 425.63 Mn |
| Dec 31, 2023 | 457.84 Mn |
| Sep 30, 2023 | 478.35 Mn |
| Jun 30, 2023 | 525.07 Mn |
| Mar 31, 2023 | 544.92 Mn |
| Dec 31, 2022 | 527.41 Mn |
| Sep 30, 2022 | 659.53 Mn |
| Jun 30, 2022 | 677.25 Mn |
| Mar 31, 2022 | 759.58 Mn |
| Dec 31, 2021 | 803.41 Mn |
| Sep 30, 2021 | 624.83 Mn |